Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Frontline 4-Drug Atezolizumab Regimen Shows Tolerability and Minimal Treatment Burden in NSCLC

June 11th 2020

The 4-drug ABCP regimen improved survival while maintaining good health-related quality of life in patients with nonsquamous non–small cell lung cancer, according to patient-reported outcomes from the phase 3 IMpower150 trial.

Dr. Lopategui on the Evolution of Targeted Therapies in NSCLC

June 5th 2020

Jean Lopategui, MD, discusses the evolution of targeted therapies in non–small cell lung cancer.

Dr. Husain on Common Misconceptions in Lung Cancer

June 5th 2020

Hatim Husain, MD, discusses common misconceptions that still exist with regard to lung cancer.

Dr. Rodriguez-Abreu on Updated Results From the KEYNOTE-189 Trial in NSCLC

June 5th 2020

Delvys Rodriguez-Abreu, MD, discusses findings from the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non–small cell lung cancer.

Getting Ready for the Next Chapter in Lung Cancer

June 4th 2020

David R. Gandara, MD, an esteemed lung cancer specialist and 2017 Giants of Cancer Care® award winner, views himself not only as a physician-scientist, but also as an educator and communicator.

DUBLIN-3 Trial With Plinabulin in Advanced NSCLC to Continue Without Modifications

June 4th 2020

The Data and Safety Monitoring Board has advised that the phase 3 DUBLIN-3 trial of the antineoplastic agent plinabulin in patients with advanced or metastatic non–small cell lung cancer who have progressed on standard-of-care therapy can continue without any modifications.

Dr. Rotow on Results of a Phase 1/2 Trial With Osimertinib/Gefitinib in EGFR-Mutant NSCLC

June 3rd 2020

Julia K. Rotow, MD, discusses the results of an ongoing phase 1/2 trial evaluating the safety and efficacy of osimertinib in combination with gefitinib as a first-line treatment for patients with stage IV EGFR-mutant non–small cell lung cancer.

Dr. Rodriguez-Abreu on the Final Analysis of the KEYNOTE-189 Trial in NSCLC

June 2nd 2020

Delvys Rodriguez-Abreu, MD, discusses the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non–small cell lung cancer.

Dr. Herbst on the Benefit of Adjuvant Osimertinib in EGFR-Mutant NSCLC

June 2nd 2020

Roy S. Herbst, MD, PhD, discusses the benefit of adjuvant osimertinib demonstrated in patients with stage II to IIIA EGFR-mutant non–small cell lung cancer in the phase 3 ADAURA trial.

Alectinib Continues to Maintain Significant OS Benefit in ALK+ NSCLC

June 1st 2020

The highly selective second-generation TKI alectinib demonstrated a clinically meaningful improvement in overall survival compared with crizotinib in patients with ALK-positive non–small cell lung cancer.

Tepotinib Displays Durable Clinical Benefit in METex14-Altered NSCLC

May 31st 2020

The oral, highly selective MET inhibitor tepotinib demonstrated durable clinical activity in patients with locally advanced or metastatic non–small cell lung cancer who harbor a MET exon 14 skipping mutation identified through liquid or tissue biopsy.

Tislelizumab Frontline Combos Extend PFS in Squamous NSCLC

May 31st 2020

Combining the anti–PD-1 agent tislelizumab with chemotherapy improved progression-free survival compared with chemotherapy alone as a frontline treatment in Chinese patients with advanced squamous non–small cell lung cancer.

Frontline Durvalumab Maintains OS Benefit in Extensive-Stage Small Cell Lung Cancer

May 31st 2020

The addition of durvalumab to standard chemotherapy continued to demonstrate an improvement in overall survival for patients with treatment-naïve extensive-stage small cell lung cancer.

AMG 510 Shows Clinical Activity in Advanced KRAS G12C-Mutant Solid Tumors

May 30th 2020

AMG 510, a novel KRAS G12C inhibitor, demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors other than non–small cell lung cancer and colorectal cancer.

FDA Approves Ramucirumab Plus Erlotinib for Frontline EGFR+ NSCLC

May 30th 2020

The FDA has approved the combination of ramucirumab and erlotinib as a frontline treatment for patients with metastatic non–small cell lung cancer whose tumors harbor EGFR mutations.

Dr. Santos on the FDA Approval of Ramucirumab/Erlotinib in EGFR-Mutant NSCLC

May 30th 2020

Edgardo S. Santos, MD, FACP, FCCP, discusses the FDA approval of the combination of ramucirumab and erlotinib for the frontline treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors harbor EGFR Ex19del or Ex21 substitution mutations.

Frontline Nivolumab/Ipilimumab Combo with Limited Chemo Improves OS in NSCLC

May 30th 2020

Results from the CheckMate 9LA suggested that frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer should be considered a new option for this population.

Pembrolizumab Added to Etoposide Plus Platinum Chemotherapy Provides Modest Survival Benefit in ES-SCLC

May 29th 2020

Modest survival benefits were observed in patients with extensive-stage small cell lung cancer who received the combination of pembrolizumab and etoposide plus platinum compared with patients who received EP and placebo.

Nivolumab/Ipilimumab Combo Induces Durable Responses in Advanced NSCLC

May 29th 2020

Following at least 3 years of follow-up, patients with advanced non-small cell lung cancer and tumor PD-L1 expression ≥ 1% or < 1% experienced durable and long-term efficacy benefits from frontline treatment with nivolumab plus ipilimumab, compared with chemotherapy.

Trastuzumab Deruxtecan Induces Durable Responses in HER2-Mutant NSCLC

May 29th 2020

Fam-trastuzumab deruxtecan-nxki demonstrated favorable clinical activity with a high objective response rate and durable responses in patients with HER2-mutated non–small cell lung cancer.